Alumni
Cantargia
Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, as well as our discovery project CANxx. CAN04 is designed to block the cancer cell’s signalling via the interleukin-1 system. Thereby the tumour inflammation, which facilitates the growth of the tumour, can be counteracted. CAN04 is also designed to stimulate the body’s immune system to eliminate cancer cells directly.
Göran Forsberg has a PhD in biochemistry, and is an associate professor and the author of over 40 scientific publications. For more than 30 years he has had different positions in research and development, business development and investor relations at pharmaceutical and biotechnology companies, including KabiGen, Pharmacia, Active Biotech and the University of Adelaide, Australia. Forsberg has extensive experience in leading drug development and clinical trials, with a special focus on oncology. Forsberg is a board member of Guard Therapeutics International AB (publ).
Did you know?
Cantargia is listed on OMX Stockholm’s Main List (Small Cap).